Exits & Floats
Crombie Anderson provides intelligent, targeted and strategic design and streamlines its creativity through two divisions: Product Design: industrial, mechanical, electronic, and optical design & Graphic Communications: corporate and brand identity, sales and marketing literature, exhibition graphics and web design. Crombie Anderson combines design skills to provide a turnkey solution, or uses particular aspects of its creativity to deliver strategic design to key areas. Crombie Anderson works by establishing the best fit development team from its established network of highly skilled individuals.
Data Discoveries supplies businesses easy to use software, which combines access to fourteen databases. This offers the ability to capture names & addresses easily and accurately allowing clients to cleanse and enhance databases; profile new & potential customers and trace individuals. Used by marketeers, financial institutions, government bodies and debt collectors, capabilities can be installed on users' own systems or accessed across the web for low-cost-of-entry and up to date data. Data Discoveries are specialists in both business to consumer and business to business markets.
Flexitricity, is the first open-market system allowing electricity customers to participate directly in balancing supply and demand in the electricity system. Flexitricity uses advanced networking technology linked to a number of existing standby generators and electricity consuming processes. By starting generators and stopping consumption during periods of stress in the electricity system, Flexitricity helps keeps the system secure and reduces carbon dioxide emissions associated with electricity generation. Flexitricity is being rolled out in the UK, the world's most developed electricity market, but is applicable worldwide. Flexitricity was successfully sold to Alpiq, a Swiss energy company, in April 2014.
With systems now sold across 5 continents, Lab901's revolutionary ScreenTape product automates a traditional bio-analysis process used by thousands of scientists and clinicians around the world. ScreenTape enables diagnostic and life science research labs to achieve rapid and accurate results effortlessly.
Mpathy Medical is a rapidly growing medical device company which has developed and brought to market a range of surgical solutions used to restore pelvic health to women. Mpathy Medical’s core product lines - Restorelle®, Omnisure™, and Minitape® - are used by surgeons specializing in urogynecology, gynecology, and urology to treat female stress urinary incontinence (SUI) and pelvic organ prolapse (POP).
Mpathy Medical supplies the only mesh surgical solutions designed specifically for the female anatomy. The mesh - branded Smartmesh® - is a physiologically compatible, ultra lightweight polypropylene mesh which encourages superior collagen growth and works in concert with the patient’s own natural tissue for optimum safety and results.
The company was sold to Coloplast in November 2010 however the shareholders still have an interest in the company through an earnout arrangement.
Optos' platform technology is the Panoramic200 Scanning Laser Ophthalmoscope device, known as the P200. In a quarter of a second the P200 produces a high resolution image of up to 200 degrees or approximately 82% of the retina in a single capture. The image, branded the optomap Retinal Exam, provides eye care practitioners with clinically useful information that facilitates the early detection of disorders and diseases evidenced in the retina, such as glaucoma, diabetic retinopathy and age-related macular degeneration. Retinal imaging can also indicate evidence of non-eye or systemic diseases such as diabetes, hypertension and certain cancers. Optos' technology provides an unequalled combination of ultra-widefield retinal imaging, speed and convenience for both practitioner and patient and can help save sight and save lives.
Stem Cell Sciences PLC
Stem Cell Sciences plc (SCS, AIM:STEM, ASX: STC), the global biotechnology company focused on the commercialisation of stem cells and stem cell technologies in research and cell-based therapies.
Vitrology is a Biopharmaceutical Contract Research Organisation (CRO). Vitrology assists clients address regulatory concerns around viral safety and other related biosafety issues, allowing them to enter clinical trials or market a licensed biological product.
By working in close collaboration with clients from the early stages of their new drug discovery and development programs, tailoring advice and extending services to meet the precise requirements of each project. Additionally Vitrology develops, conducts and validates custom studies, devising innovative testing procedures, and addressing the unique test specifications required for novel therapeutics. Vitrology was successfully sold to SGS in May 2012